Real-World data reveals palbociclib use in japanese breast cancer patients
NCT ID NCT05153187
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed medical records of 1,170 advanced breast cancer patients in Japan to see how they used the drug palbociclib (Ibrance). Researchers looked at blood test frequency and how long patients stayed on treatment. The goal was to describe real-world treatment patterns, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palbociclib (Ibrance)
What this could lead to
If successful, this could help doctors better understand how palbociclib is used in real-world settings, potentially improving treatment guidelines for advanced breast cancer in Japan.
What could go wrong
This is an observational study that only describes existing data, not testing a new treatment. It cannot prove what works best, and results may not apply outside Japan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Japan
Tokyo, Japan